EIF2AK3 and neoplasm: Hypoxia, a hallmark of tumor cells and a key driver of malignancy and drug resistance(Yang et al. 2022), is counteracted by the PERK/eIF2α signaling pathway, which stimulates cysteine uptake, glutathione synthesis, and controls oxidative stress to safeguard hypoxia-tolerant cells(Rouschop et al. 2013).